Showing results (241-250 of 279) with videos related to

Sort By:
Pageof 28
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2018
LSD1 activates a lethal prostate cancer gene network independently of its demethylase functionArchana Sehrawat, Lina Gao, Yuliang Wang, et al.
Pageof 28